Overview

A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide